EFFECT OF EUDRAGIT® E PO QUANTITY ON BITTER TASTE-MASKING OF DICLOFENAC SODIUM IN ORALLY DISINTEGRATING TABLETS
Main Article Content
Abstract
Bitter taste-masking of diclofenac sodium (DS) was prepared by forming solid dispersion of drug and polymer using solvent method. Polymeric materials used were ethyl cellulose (EC) or polymethacrylates E PO (Eudragit® E PO). Drug and polymer ratios were varied in the range of 1:1, 1:2, 1:3, and 1:4. Drug dissolution of solid dispersion powders were tested in simulated saliva fluid (SSF). Comparing to the drug (DS), increasing amount of polymer in the preparations decreased drug dissolution and reduced the bitter taste of drug. Drug released was retarded due to drug entrapment in the polymer. Because of stickiness and difficulty for size reduction of EC preparations at the ratio of 1:2 and higher, Eudragit® E PO preparation was selected for tablet preparation. Orally disintegrating tablets (ODTs) of drug (DS ODTs) were prepared by direct compression. Effect of superdisintegrant type and quantity on disintegration time was studied. ODTs of 5% by weight of crosslinked polyvinylpyrrolidone (P5) showed the fastest disintegration time. ODTs with taste-masked DS (solid dispersion of drug to Eudragit® E PO, 1:3) were prepared in the same manner of P5 and gave faster disintegration time than DS ODTs (13.15 second and 22.57 second, respectively). The percentage of drug released from taste-masked DS ODTs was lower than that from DS ODTs in SSF. (39.13% and 91.26% at 5 minutes, respectively) In vitro taste-masking in 10 mL SSF was tested at 1, 3 and 5 minutes. Drug released of DS from taste-masked ODTs at various times were significant lower than those from DS ODTs (6.92, 9.48, 7.31 mcg/mL and 45.68, 67.40, 49.03 mcg/mL at 1, 3 and 5 minutes, respectively). Eudragit® E PO could be used for taste-masking of bitter drug powder and drug bitterness was reduced with the increasing in the amount of polymer in the preparation.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Journal of TCI is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) licence, unless otherwise stated. Please read our Policies page for more information.
References
Kulkarni AP, Khedkar AB, Lahotib SR, Dehghanb M. 2012. Development of oral disintegrating tablets of rizatriptan benzoate with inhibited bitter taste. Am-Euras. J. Sci. Res.7(2):47-57.
Lai et al. 2009. Taste-masked pharmaceutical compositions prepared by coacervation. United States Patent Application Publication. Pub. No. US 2009/0263480 A1.
Pradhan R, Kim SY, Yong CS, Kim JO. 2016. Preparation and characterization of spray-dried valsartan-loaded Eudragit® E PO solid dispersion microparticles. Asian J. Pharm. Sci. 11:744-750.
Siewert M, Dressman J, Brown CK, Shah VP. 2003. FIP/AAPS Guidelines to dissolution/in vitro release testing of novel/special dosage forms. AAPS PharmSciTech.4(1) Article 7:1-10.
Sona PS, Muthulingam C. 2011. Formulation and evaluation of taste masked orally disintegrating tablets of diclofenac sodium. Int.J.PharmTech Res. 3(2): 819-826.
The Department of Health, Great Britain. The Department of Health, Social, Services and Public Safety, Northern Ireland. 2015. British Pharmcopoeia. Volume V. London: The Stationary Office. Appendix XII C V-371.
The United States Pharmacopeia. The National Formulary. 2014. USP37 and NF32. Volume 1.2. Rockville: The United States Pharmacopeial Convention, Rockville.
U.S. Food and Drug Administration, Center for Drug Evaluation and Research (CDER). 2008. Guidance for Industry: Orally Disintegrating Tablets. Retrieved from https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070578/orally-disintegrating_tablets_final_FDA_8528fnl.pdf, accessed Dec.14, 2017.
Yan Y, Woo JS, Kang JH, Yong CS, Choi H. 2010. Preparation and evaluation of taste-masked donepezil hydrochloride orally disintegration tablets. Biol. Pharm. Bull. 33(8):1364-1370.